| Developer says Cel-Sci's L.E.A.P.S. technology has extensive applications | | Print | |
| Written by M.E.Garza | ||||||||||||||||||||
| Monday, 19 October 2009 00:00 | ||||||||||||||||||||
 While Dr. Daniel Zimmerman of Cel-Sci Corporation (AMEX:CVM) and his team have been spending a great deal of time and energy working on the company's investigational LEAPS-H1N1 treatment, this past weekend the focus shifted to another illness which causes fatigue, loss of appetite, widespread muscle aches and weakness.
New rheumatoid arthritis data presented at the American College of Rheumatology's annual meeting in Philadelphia by Dr. Zimmerman in conjunction with several collaborators from Washington Biotech, Northeastern Ohio Universities College of Medicine and BolderBiopath, indicated that CEL-SCI's rheumatoid arthritis treatment vaccine CEL-2000, based upon the company's L.E.A.P.S. technology, acts to prevent or retard the permanent tissue damage caused by rheumatoid arthritis in animals. These statistically significant results are the latest positive notch on the belt for L.E.A.P.S., but the scientific journey for technology has been a long, meticulous one. "I've been working on this technology for over twenty years," explains Zimmerman, "We've stuck with it since 1987, firmly believing in it, being the key developer for it. Things are finally starting to take off. We're seeing now that the applications are as extensive as we thought that they would be originally in the areas of infectious diseases, autoimmune, perhaps even cancer and other types of conditions, but we've been limited in our resources so we had to concentrate on some key areas, hence the rheumatoid arthritis results." CEL-SCI’s much discussed H1N1 treatment is based on the same treatment platform and the U.S. Food and Drug Administration (FDA) was intrigued enough by the potential of Dr. Zimmerman's work that the company was given an expedited go-ahead to proceed with its first clinical trials involving human models. The company hopes the same results which were achieved through a reduction of inflammatory response will be the same for their new H1N1 treatment for H1N1 hospitalized patients. "Many of these patients die from the excessive inflammatory response," Geert Kersten, Chief Executive Officer of CEL-SCI said in a prepared statement. "We feel that this new data is encouraging both for this rheumatoid arthritis vaccine as well as supportive of our H1N1 treatment." "It's really getting quite exciting," said Zimmerman. "We've done several studies and we're seeing very good therapeutic benefit of the technology as accessed by several number of criteria, it's not just one criteria." During the presentation dealing with rheumatoid arthritis on Sunday, the researchers demonstrated the measurement of four different parameters alone for vaccine and each of them was backed with remarkable scientific data. What made the medical community at the presentation take note of the CEL-2000 vaccine was it's proposed use as a treatment for the debilitating pain, stiffness and inflammation that wreaks havoc from rheumatoid arthritis. "The therapeutic vaccination is actually a vaccine that's given after the disease symptoms have started appearing and developing, so it's not something that is given before the disease has become apparent. We're actually waiting until we see disease symptoms." What may intrigue investors further are the technology's implications that reach beyond the H1N1 and rheumatoid arthritis spaces. "We have some other work (in treating other diseases) which has not been presented as yet and I'm not yet at liberty to discuss that because our collaborators have not yet announced that or presented it and I don't want to preempt them on that, " explains Zimmerman. "We are looking at several different systems." Developing... BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section Add this page to your favorite Social Bookmarking websites           
Set as favorite
Bookmark
Email this
Trackback(0)
Comments (5)
Dr. Chaturvedi
said:
|
TrackBack URI for this entry
Subscribe to this comment's feed|
... Dear Mr. Garza: Thanks for updating about Cell-Sci (AMEX:CVM). I am so delighted to know the progress of the thier Techology and its application in future for treating the devastating human diseases such as Arthritis, Swine flu and cancer etc. Dr. LS Chaturvedi PS: I know some people at STREET.COM are not knowing the importance of it but one day sooner or later will realise the importance thier technology. |
|
Carl Fossaceca
said:
|
... As a clinical pharmacist working in a community hospital with a busy cancer center, I am exposed to new medications and drug delivery systems on a daily basis. For many years, I have watched big pharmaceutical giants dump billions of dollars to beat down the immune system in the treatment of cancer. However, we all knew that the only "right way" to treat cancer and other autoimmune diseases would be to activate and simulate the immune system to recognize "self" and "non-self". Cel-Sci has finally begun the process of changing the way we treat these diseases, and those nay-sayers are doing their best to beat companies like Cel-Sci down. I don't get it. Instead of killing the patient while attempting to kill the cancer, shutting down our immune systems, we should be recognizing and supporting the new 21st century technologies and soon-to-be breakthroughs. Honestly, I have read as much of the medical literature and studies involved in the L.E.A.P.S technology, and I have not been able to find one fellow pharmacist, physician, or PhD who can tell me what is wrong with this new breakthrough technology. In clsoing, let's get behind this, either by supporting companies like Cel-Sci willing to take that chance, or by stop listening to those folks eager to get a name for themselves via negative publicity. I, too, am looking forward to the day in the not-too-distant future when Cel-Sci's technologic breakthroughs improve the lives of millions of people throughout the world by defeating cancer and other autoimmune diseases! |
|
R5c9t1
said:
|
... To Carl Fossaceca: Seriously, current anti-cancer therapies have been established long before anyone knew anything about how cancer cells escape immune recognition. And they, even as toxic as they are, save quite a large proportion of patients and prolong the life of many others. It took decades to establish valid protocols and collaborations between the best scientists and clinicians all over the world, a long journey that began long before words like T lymphocyte / dendritic cell were even known. I can understand you are excited about new immune intervention in cancer therapy, but your statements seem far too careless and diminishing the excellent work of countless people, not to mention that there are quite a few companies out there busy developing vaccines against tumor specific antigens and others busy studying mechanisms of growth that regulate tumor cells. Having said all that, Cel Sci may be on the right direction, along with many others, to provide a solution that takes into account recent scientific knowledge. For now they have produced some results in preclinical studies, let's see how it goes in clinical trials. |
|
al crespo
said:
|
... Dear M. E. As a holder of Cel-Sci stock, I have become concerned with the current tit for tat that is now playing out between you and Adam Feurstein. Feurstein's pieces are clearly designed more as slanted opinion pieces than factual reporting and have resulted in undermining the credibility of the management and bringing down the PPS of Cel-Sci several times in the last month. While this is obviously damaging, I don't believe that your constant need to counter his pieces is accomplishing much more than supporting the belief by some that this is more about a pissing match between you guys than whether Cel-Sci is a worthwhile company worthy of investment. As a stockholder who has been forced by all of this nonsense to spend more time than I wanted to go reviewing financial records and filings I can tell you that I'm not necessarily reassured by claims such as the one above that states: "It's really getting quite exciting," said Zimmerman. "We've done several studies and we're seeing very good therapeutic benefit of the technology as accessed by several number of criteria, it's not just one criteria." I believe that I can speak for a lot of stockholders in saying that we are more than willing to forgo more excitement for more factual accomplishment. One issue that has sparked my curiosity are the continuing claims by Cel-Sci about their manufacturing facility in Maryland. All of the comments about the on-going construction of their facility, including the photographs on their website are dated 2008. I think it would be a benefit for all of us who cannot visit the site personally for someone from Cel-Sci to take some NEW photographs revealing whether or not the facility is actually completed and equipped. The claims by Cel-Sci that the testing of the facility started in July of 2009, without there being any projected completion date only serves to raise questions about just what this company is capable of completing successfully. Especially since they've admitted in an SEC filing that they were even unable to make their lease payment last December. As for the antics of Adam Feurstein and his continuing bombardment of Cel-Sci, one core discovery in his series of pieces stands out as both troubling and a plant. Who was - or is - the mysterious "Dr. Palbo Romanus"? While Cel-Sci and its stockholders could see some benefit to their PPS from the positive article that "Dr. Romanus" is credited with writing, it would seems that the real beneficiary of "Dr. Romanus" accrued to Adam Feurstein in his unmasking the good doctor as a fake. It was gotcha journalism at its finest. Or was it? Given the impact that Feurstein's revelation about "Dr. Romanus" has had on both the PPS and the questions of the management's credibility, I would think that this whole episode warrants the investigation of a real reporter or by investigators of one of the regulatory agencies. In addition, I think that the webmaster and publisher at American Chronicle has a responsibility to do their own investigation - and publish the results about "Dr. Romanus" on their site - given that "Dr. Romanus" used their website to post his article and subsequent rubuttal to Feurstein's piece about him. In addition to these and other questionable issues, I have just learned that Cel-Sci has just filed an SEC filing to sell another 39,790,790 shares of common stock, and has provided information that on its face would question in any reasonable person the degree of "excitment" expressed by Dr. Zimmerman in your article above. I initially became aware of, and an investor in Cel-Sci in large part because of your September pieces on Cel-Sci and of the promise that I thought was possible in the L.E.A.P.S. technology. I still hold some hope that promise is real, but I am more that a little disturbed that instead of simply investing in a stock that held some promise and dealing with the inherent anxieties that accompany such an undertaking, I'm now a passive participant in a pissing match between you and Mr. Feurstein, while a Greek Chorus of largely financially ignorant nitwits brays on bulletin boards about short selling conspiracies and the parentage - or lack thereof - of their fellow board members, while the value of my investment keeps tanking. I appreciate what you do M.E., and quite frankly, even if you're making big money from your FDA Calendar, I'm not necessarily sure it would justify getting snippy letters from someone like Adam Feurstein questioning your integrity. However, I would ask that if you're going to do any more pieces on Cel-Sci, you rely less on the claims of "excitement" by the management, and more on some hard hitting, factual information of just what is really going on with this company, and when if ever, are they going to actually see something come to fruition. Sincerely, Al Crespo www.thephotoworksagency.com |
|
DR. Frederick Oddi
said:
|
... There is no denying that this is the technology of the future.There are times after years of tedious work that science can leapfrog forward in a giant step.This is such a technology. Where are the grants , government and private? Giant Pharma does not want its multi multi billiom dollar cancer and disease buisenes disrupted .There is more money in treating and not curing ,than curing disease. It will take longer but progress cannot be stopped! |
|
Write comment
Sign Up For Phone Alerts
